文献速递妇科

妇科恶性肿瘤盆腔廓清术的临床结局

Clinical outcomes of pelvic exenteration for gynecologic malignancies.
PubMed 文献 · Gynecol Oncol · 2023-03-02

荷兰三家三级医疗中心20年间90例妇科恶性肿瘤盆腔廓清术患者的回顾性分析显示,92%出现至少一种并发症,61%发生重大并发症,放疗患者重大并发症风险更高;中位总生存25个月,2年总生存率51.1%,切缘阳性、肿瘤大小及盆壁受累与不良生存相关。

要点

  • 盆腔廓清术后并发症常见(92%至少一种并发症,61%重大并发症),放疗患者重大并发症风险更高。
  • 中位总生存25个月,2年总生存率51.1%;中位无进展生存14个月,2年无进展生存率41.5%。
  • 切缘阳性、肿瘤大小及盆壁受累与较差生存结局相关,需充分选择可从手术获益的患者。

核心结论

  • 妇科恶性肿瘤盆腔廓清术后并发症常见,尤其在放疗患者中;本研究报告2年总生存率为51.1%。
  • 切缘阳性、肿瘤大小及盆壁受累与不良生存结局相关,充分选择可从盆腔廓清术获益的患者很重要。

研究设计与样本

  • 回顾性分析了荷兰三家三级医疗中心(Leiden University Medical Centre、Amsterdam University Medical Centre、Netherlands Cancer Institute)妇科肿瘤科20年间所有接受盆腔廓清术的患者。
  • 共纳入90例患者,最常见原发肿瘤为宫颈癌(n=39,43.3%)。

主要发现

  • 83例(92%)观察到至少一种并发症,55例(61%)发生重大并发症;放疗患者发生重大并发症的风险更高。
  • 62例(68.9%)需要至少1次再入院,40例(44.4%)需要再次手术。
  • 中位总生存25个月,中位无进展生存14个月;2年总生存率51.1%,2年无进展生存率41.5%。
  • 肿瘤大小、切缘及盆壁受累对总生存有负面影响(HR=2.159、HR=2.376、HR=1.200)。
  • 切缘阳性及盆壁受累导致无进展生存下降(HR=2.567、HR=3.969)。

临床怎么用

  • 原文结论指出,充分选择将从盆腔廓清术获益的患者很重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to analyze morbidity and survival after pelvic exenteration for gynecologic malignancies and evaluate prognostic factors influencing postoperative outcome. METHODS: We retrospectively reviewed all patients who underwent a pelvic exenteration at the departments of gynecologic oncology of three tertiary care centers in the Netherlands, the Leiden University Medical Centre, the Amsterdam University Medical Centre, and the Netherlands Cancer Institute, during a 20-year period. We determined postoperative morbidity, 2- and 5-year overall survival (OS) and 2- and 5-year progression free survival (PFS), and investigated parameters influencing these outcomes. RESULTS: A total of 90 patients were included. The most common primary tumor was cervical cancer (n = 39, 43.3%). We observed at least one complication in 83 patients (92%). Major complications were seen in 55 patients (61%). Irradiated patients had a higher risk of developing a major complication. Sixty-two (68.9%) required ≥1 readmission. Re-operation was required in 40 patients (44.4%). Median OS was 25 months and median PFS was 14 months. The 2-year OS rate was 51.1% and the 2-year PFS rate was 41.5%. Tumor size, resection margins and pelvic sidewall involvement had a negative impact on OS (HR = 2.159, HR = 2.376, and HR = 1.200, respectively). Positive resection margins and pelvic sidewall involvement resulted in decreased PFS (HR = 2.567 and HR = 3.969, respectively). CONCLUSION: Postoperative complications after pelvic exenteration for gynecologic malignancies are common, especially in irradiated patients. In this study, a 2-year OS rate of 51.1% was observed. Positive resections margins, tumor size, and pelvic sidewall involvement were related to poor survival outcomes. Adequate selection of patients who will benefit from pelvic exenteration is important.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Moolenaar LR, van Rangelrooij LE, van Poelgeest MIE, et al. Clinical outcomes of pelvic exenteration for gynecologic malignancies. Gynecol Oncol. 2023. PMID: 36870097. doi:10.1016/j.ygyno.2023.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。